GRI Bio, Inc.

NasdaqCM:GRI

Market Cap

USD 3.29 M

Share Price

USD 1.30

Avg Daily Volume

497,880

Change (1 day)

-7.14%

Change (1 year)

Change (YTD)

-85.84%

GRI Bio, Inc. Price to Sales Ratio (P/S) on June 13, 2025

GRI Bio, Inc. Price to Sales Ratio (P/S) is NA on June 13, 2025. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • GRI Bio, Inc. 52-week low Price to Sales Ratio (P/S) is 1.22 on June 13, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • GRI Bio, Inc. 52-week low Price to Sales Ratio (P/S) is 0.05 on June 13, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • GRI Bio, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 0.58.
Key data
Date Price to Sales Ratio (P/S) Enterprise Value to EBITDA (EV/EBITDA) Free Cash Flow Yield Dividend Yield
Market news
Loading...
NasdaqCM: GRI

GRI Bio, Inc.

CEO Dr. W. Marc Hertz Ph.D.
IPO Date Feb. 10, 2021
Location United States
Headquarters 2223 Avenida de la Playa
Employees 3
Sector 🏥 Health Care
Industries
Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Similar companies

IKNA

Ikena Oncology, Inc.

USD 1.35

-1.46%

STTK

Shattuck Labs, Inc.

USD 1.01

-5.61%

GLUE

Monte Rosa Therapeutics, Inc.

USD 4.91

-0.20%

HCWB

HCW Biologics Inc.

USD 5.45

-0.91%

CELC

Celcuity Inc.

USD 12.11

-3.58%

EWTX

Edgewise Therapeutics, Inc.

USD 15.29

-0.84%

CCCC

C4 Therapeutics, Inc.

USD 1.68

3.70%

DSGN

Design Therapeutics, Inc.

USD 3.84

-1.79%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.39

9.45%

HOWL

Werewolf Therapeutics, Inc.

USD 1.22

-5.43%

StockViz Staff

June 17, 2025

Any question? Send us an email